What is VOR's market cap?

$1.24B, based on the Nov 4 close of $20.12.

What is VOR's P/E ratio?

0.9× trailing-twelve-month earnings of $1.35B.

Does Vor Biopharma pay a dividend?

No regular cash dividend has been paid in the last year.

How much of VOR is sold short?

7.4M shares, 17.6% of float, as of Oct 15, 2026.

What sector is VOR in?

Healthcare, in the Biotechnology industry.

NASDAQ · VORHealthcareBiotechnology

Vor Biopharma Inc. Common Stock (VOR)

$20.12+1.31%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$20.12▼ 2.14% in range

Nov 4, 2025Low $6.86 · High $25.10Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Vor Biopharma closed at $20.12 on Nov 4, up 1.31%, 19.8% below its 52-week closing high. Volume of 416.2K shares was 0.50× its 20-day average (below normal).

Split-adjusted performance: +9.9% over one month, +26.5% over six months, -10.2% over one year.

Short interest was 7.4M shares at the Oct 15 settlement, down 4.7% from the prior report (17.6% of float, 9.0 days to cover).

Market cap$1.24B61.4M shares

Revenue · quarter$0.00—

Diluted EPS$-1.45—

P/E · TTM0.9×

Net margin—

Dividend yieldNone

52-week range6.86 – 25.10−19.8% from high

Volume416.2K0.50× 20-day avg

Volatility · 60d59.2%Annualised

Short % of float17.6%9.0 days to cover

Net cash$481.6MCash $481.6M

Next earnings—Not scheduled

Split-adjusted performance

1W −2.6%1M +9.9%3M −15.1%6M +26.5%YTD +53.8%1Y −10.2%3Y −51.6%5Y −93.6%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum81

Revenue growth—

Net margin—

Value (low P/E)92

Size73

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →

Shares short7.4M−4.7% vs prior

Days to cover9.0Settled Oct 15

% of float17.6%

Short vol. 10d54.2%of daily volume

Closest peers by size in Biotechnology

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
VORVor Biopharma	$20.12	+1.31%	+26.5%	—	—	0.9	$1.24B
INBXInhibrx Biosciences	$86.76	+7.01%	−38.8%	−100.0%	—	—	$1.28B	Compare
TSHATaysha Gene Therapies	$4.36	+6.60%	−37.5%	−100.0%	—	—	$1.42B	Compare
ODTXOdyssey Therapeutics	$19.50	−9.60%	—	—	—	—	$937.1M	Compare
GLUEMonte Rosa Therapeutics	$10.82	+3.94%	−46.9%	−61.3%	−483.9%	—	$923.1M	Compare
MGTXMeiraGTx Holdings	$9.42	−1.05%	−4.8%	+8608.6%	50.0%	11.5	$904.7M	Compare
PRMEPrime Medicine	$4.97	+9.23%	+45.7%	+3.5%	−3649.0%	—	$901.4M	Compare
NVAXNovavax	$10.65	+10.02%	+13.8%	−76.3%	−94.2%	—	$1.76B	Compare
MAZEMaze Therapeutics	$33.38	+3.50%	+26.1%	—	—	—	$1.85B	Compare

News about Vor Biopharma

All news →

Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswire Inc. · 5d ago▲ Positive Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc. · Oct 5, 2026▲ Positive

Quick answers

What does Vor Biopharma do?: Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.
What is VOR's market cap?: $1.24B, based on the Nov 4 close of $20.12.
What is VOR's P/E ratio?: 0.9× trailing-twelve-month earnings of $1.35B.
Does Vor Biopharma pay a dividend?: No regular cash dividend has been paid in the last year.
How much of VOR is sold short?: 7.4M shares, 17.6% of float, as of Oct 15, 2026.
What sector is VOR in?: Healthcare, in the Biotechnology industry.

About Vor Biopharma

Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.

HQ: Boston, MA76 employeesListed Feb 5, 2021vorbio.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology